Filtered By:
Condition: Cholesterol
Drug: Atorvastatin Calcium
This page shows you your search results in order of date.
Order by Relevance | Date
Total 26 results found since Jan 2013.
Cardiac Alarmins as Residual Risk Markers of Atherosclerosis under Hypolipidemic Therapy
Int J Mol Sci. 2022 Sep 22;23(19):11174. doi: 10.3390/ijms231911174.ABSTRACTIncreased levels of low-density lipoproteins are the main risk factor in the initiation and progression of atherosclerosis. Although statin treatment can effectively lower these levels, there is still a residual risk of cardiovascular events. We hypothesize that a specific panel of stress-sensing molecules (alarmins) could indicate the persistence of silent atherosclerosis residual risk. New Zealand White rabbits were divided into: control group (C), a group that received a high-fat diet for twelve weeks (Au), and a treated hyperlipidemic group wit...
Source: Atherosclerosis - October 14, 2022 Category: Cardiology Authors: Viorel I Suica Elena Uyy Luminita Ivan Raluca M Boteanu Aurel Cerveanu-Hogas Rune Hansen Felicia Antohe Source Type: research
Dual targeted delivery of statins and nucleic acids by chitosan-based nanoparticles for enhanced antiatherosclerotic efficacy
Biomaterials. 2021 Dec 15;280:121324. doi: 10.1016/j.biomaterials.2021.121324. Online ahead of print.ABSTRACTCardiovascular disease caused by atherosclerosis is a leading cause of morbidity and mortality worldwide. Owing to the synergistic regulation of cholesterol metabolism and lesion inflammation, the simultaneous administration of statins and nucleic acids is expected to alleviate atherosclerosis. In this work, we prepared atorvastatin- and galactose-modified trimethyl chitosan nanoparticles (GTANPs) with dual targeting to hepatocytes and lesional macrophages for encapsulating Baf60a siRNA (siBaf60a) and anti-miR-33 pD...
Source: Biomaterials - December 21, 2021 Category: Materials Science Authors: Ting Jiang Lu Xu Mengxin Zhao Fei Kong Xinrong Lu Cui Tang Chunhua Yin Source Type: research
Atorvastatin Induces FXR and CYP7A1 Activation as a Result of the Sequential Action of PPAR γ/PGC-1α/HNF-4α in Hep3B Cells
CONCLUSIONS: Atorvastatin induces FXR and CYP7A1 activation as a result of sequential action of PPARγ-PGC-1α-HNF-4α in human hepatocytes. We propose that atorvastatin enhances solubility of cholesterol in bile by simultaneously activating of FXR and CYP7A1.PMID:33686046 | DOI:10.4166/kjg.2020.156
Source: Korean J Gastroenter... - March 9, 2021 Category: Gastroenterology Authors: Jin Lee Eun Mi Hong Jang Han Jung Se Woo Park Sang Pyo Lee Dong Hee Koh Hyun Joo Jang Sea Hyub Kae Source Type: research
